Cyntellect Awarded $1.3MM Phase II SBIR Grant to Automate Cloning of Cells Based on Protein Secretion

16-May-2007

Cyntellect, Inc. announced it will receive approximately $1.3MM in funding under a Phase II Small Business Innovative Research (SBIR) grant for continued new application development on its laser-based LEAP(TM) system.

Specifically, the grant will fund further development of applications using LEAP for automated highspeed purification and cloning of cells based upon their specific secretion of native or recombinant proteins.

"The ability to perform high-speed purification and cloning of cells based on various functional cell properties, such as the secretion rate of specific proteins, opens up exciting new avenues of research activities in areas ranging from biologics discovery to cell line development to cellular diagnostics," stated Dr. Fred Koller, President and CTO. "This grant award recognizes the substantial progress reported from our Phase I efforts and highlights the significance of this LEAP application for contributing to new and important scientific discoveries."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures